Titlebook: Malignant Lymphomas: Biology and Treatment; An Update Gerassimos Alexander Pangalis (Associate Professor Conference proceedings 1995 Spring

放縱

,Treatment of Non-Hodgkin’s Diffuse Large Cell Lymphomas, that was very often fatal to one that is often curable [1]. In the last decade, multi-agent regimens have been developed in an attempt to increase both the complete response rate and long-term survival [2–5]. This improvement in complete response and survival rates has been associated with an incre

散開

nitroglycerin

Fludarabine Monophosphate, an Effective New Agent in Leukaemias and Lymphomas,e remission or cure existed. Fludarabine monophosphate, a purine analogue, was recently introduced into clinical trials for chronic lymphocytic leukaemia and low-grade non-Hodgkin’s lymphomas and found to be very effective. In this report we review the available data relating to fludarabine monophos

Ballad

Role of Haemopoietic Growth Factors in Lymphoma Therapy, and/or macrophages. These factors expand the number of dividing precursor cells and shorten the postmitotic maturation time of maturing granulocytes in the bone marrow. They have proved to be an important addition to the supportive care armamentarium in patients treated with myelosuppressive chemo-

向下五度才偏

High-Dose Therapy for the Malignant Lymphomas,hich are now generally associated with a good prognosis. Since the turn of the century [1], patients with localized disease have been cured by extended-field radiotherapy alone, at a dose of not less than 40 Gy, and the alkylating agents were introduced in 1946 [2] as treatment for patients with mor

妨礙

Malignant Lymphomas in Immunocompromised Hosts, in Particular with AIDS,immunodeficiency disorders such as the X-linked lymphoproliferative syndrome or the Wiscott Aldrich syndrome. Moreover, patients with immune deficiency secondary to cytostatic anticancer therapy and also following organ transplantation, autoimmune diseases and connective tissue disorders are at incr

irritation

High-Dose Therapy for the Malignant Lymphomas,bly provide a failure-free advantage over MOPP [5]. Non-crossresistant protocols may be used sequentially, as alternating therapy, or as multi-drug hybrid programmes intended to minimize the emergence of drug resistance.

吞吞吐吐

hed in journals and monographs. There is, however, no book that gives a concise and objective update of this information or presents a general survey of the subject. The contributors to this book are international authorities, and on the basis of their personal experience and data from the literatur

猜忌

occurrence

,Prognostic Factors in Aggressive Non-Hodgkin’s Lymphoma,ons of the lymphoma and the different histological subtypes, it is impossible to predict accurately the outcome for each patient. Large studies on the description of subgroups have been based on series of patients having the same profile and manifestations.